Last reviewed · How we verify
Nimotop (NIMODIPINE)
Nimotop (Nimodipine) is a dihydropyridine calcium channel blocker, a small molecule modality targeting the voltage-dependent L-type calcium channel subunit alpha-1F. It was originally developed and is currently owned by Azurity. FDA approved in 1988 for the treatment of subarachnoid intracranial hemorrhage, Nimotop is available as a generic medication with multiple manufacturers. Key safety considerations include its short half-life of 1.3 hours and low bioavailability of 11%. As an off-patent medication, Nimotop is widely available.
At a glance
| Generic name | NIMODIPINE |
|---|---|
| Sponsor | Azurity |
| Drug class | Dihydropyridine Calcium Channel Blocker [EPC] |
| Target | Voltage-dependent L-type calcium channel subunit alpha-1F |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 1988 |
Approved indications
- Subarachnoid intracranial hemorrhage
Boxed warnings
- DO NOT ADMINISTER NIMODIPINE INTRAVENOUSLY OR BY OTHER PARENTERAL ROUTES. DEATHS AND SERIOUS, LIFE THREATENING ADVERSE EVENTS HAVE OCCURRED WHEN THE CONTENTS OF NIMODIPINE CAPSULES HAVE BEEN INJECTED PARENTERALLY (See WARNINGS and DOSAGE AND ADMINISTRATION ).
Common side effects
- Decreased Blood Pressure
- Edema
- Headache
- Diarrhea
- Rash
- Nausea
- Dyspnea
- Tachycardia
- Bradycardia
- Muscle Pain/Cramp
- Abnormal Liver Function Test
- Acne
Drug interactions
- carbamazepine
- erythromycin
- phenobarbital
- primidone
Key clinical trials
- Pilot Study: Effects of Nimodipine on Alcohol Drinking (PHASE2)
- Nimodipine Variability in SAH
- Effect of Extracorporeal Shock Wave Therapy (ESWT) and Phonophoresis Treatment in Patients With Lateral Epicondylitis (NA)
- Delayed Cerebral Infarction Beyond Endoluminal Spasmolysis and Induced Hypertension
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Effectiveness of Calcium Channel Blockade for OP and Carbamate Pesticide Poisoning (PHASE3)
- Cilostazol With Nimodipine to Improve Outcome After Aneurysmal Subarachnoid Hemorrhage (PHASE3)
- Evaluation of Extracorporeal Shockwave Therapy and Complex Decongestive Therapy Results in Patients With Lipedema (NA)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |